On September 8, 2022 Tvardi Therapeutics, Inc. ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, reported that the management team will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 1:30 p.m. ET as well as in one-on-one meetings in New York City on Wednesday, September 14, 2022 (Press release, Tvardi Therapeutics, SEP 8, 2022, View Source [SID1234619267]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!